Transplantation in Parkinsons disease: The future looks bright

Advances in Experimental Medicine and Biology

Volumn 557, Issue , 2005, Pages 221-248

  Paul, Gesine ^a   Ahn, Young Hwan ^a   Li, Jia Yi ^a   Brundin, Patrik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASIC FIBROBLAST GROWTH FACTOR; CASPASE INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DOPAMINE; FIBRONECTIN; FLUNARIZINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LAZAROID; LEVODOPA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OXIDOPAMINE; PREDNISOLONE; TACROLIMUS; TIRILAZAD; TRANSFORMING GROWTH FACTOR ALPHA;

CELL DEATH; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DYSKINESIA; DYSTONIA; EMBRYONIC STEM CELL; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NERVE TRANSPLANTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STEM CELL; UNSPECIFIED SIDE EFFECT; AUTOPSY; CYTOLOGY; DISEASE COURSE; METABOLISM; METHODOLOGY; NERVE CELL; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PATHOPHYSIOLOGY; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA;

AUTOPSY; CELL DEATH; DISEASE PROGRESSION; DOPAMINE; DYSKINESIAS; GRAFT SURVIVAL; HUMANS; NEURONS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA;

EID: 33744512324     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (231)

1. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998a; 339:1130-1143.
2. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998b; 339:1044-1053.
3. Oertel WH, Hoglinger GU, Caraceni T et al. Depression in Parkinson's disease. An update. Adv Neurol 2001; 86:373-383.
4. Mayeux R, Chen J, Mirabello E et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990; 40:1513-1517.
5. McKeith IG, Ballard CG, Perry RH et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54:1050-1058.
6. Aarsland D, Tandberg E, Larsen JP et al. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53:538-542.
7. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988; 318:876-880.
8. Agid Y. Parkinson's disease: Pathophysiology. Lancet 1991; 337:1321-1324.
9. Benamer TS, Patterson J, Grosser DG et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. Mov Disord 2000; 15:503-510.
10. Ichise M, Kim YJ, Ballinger JR et al. SPECT imaging of pre and postsynaptic dopaminergic alterations in L- dopa-untreated PD. Neurology 1999; 52:1206-1214.
11. Kruger R, Schols L, Muller T et al. Evaluation of the gamma-synuclein gene in German Parkinson's disease patients. Neurosci Lett 2001; 310:191-193.
12. Hirsch EC, Faucheux BA. Iron metabolism and Parkinson's disease. Mov Disord 1998; 13:39-45.
13. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 1998; 13:24-34.
14. Schapira AH. Pathogenesis of Parkinson's disease. Baillieres Clin Neurol 1997; 6:15-36.
15. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002; 58:179-185.
16. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276:2045-2047.
17. Spillantini MG, Schmidt ML, Lee VM et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-840.
18. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2:492-501.
19. Lotharius J, Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002; 11(20):2395-2407.
20. Leroy E, Boyer R, Auburger G et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395:451-452.
21. Lorick KL, Jensen JP, Fang S et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA 1999; 96:11364-11369.
22. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 2001; 29:15-32.
23. Shastry BS. Parkinson disease: Etiology, pathogenesis and future of gene therapy. Neurosci Res 2001; 41:5-12.
24. Rascol O, Goetz C, Koller W et al. Treatment interventions for Parkinson's disease: An evidence based assessment. Lancet 2002; 359:1589-1598.
25. Koller W, Pahwa R, Busenbark K et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997; 42:292-299.
26. Lang AE. Surgery for Parkinson disease: A critical evaluation of the state of the art. Arch Neurol 2000; 57:1118-1125.
27. Pahwa R, Wilkinson S, Smith D et al. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997; 49:249-253.
28. Bjorklund A. Cell replacement strategies for neurodegenerative disorders. Novartis Found Symp 2000; 231:7-15.
29. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing. Trends Neurosci 1990; 13:266-271.
30. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990; 13:281-285.
31. Dunnett SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci 2001; 2:365-369.
32. Olson L, Malmfors T. Growth characteristics of adrenergic nerves in the adult rat. Fluorescence histochemical and 3H-noradrenaline uptake studies using tissue transplantations to the anterior chamber of the eye. Acta Physiol Scand Suppl 1970; 348:1-112.
33. Olson L, Seiger A. Brain tissue transplanted to the anterior chamber of the eye. 1. Fluorescence histochemistry of immature catecholamine and 5- hydroxytryptamine neurons reinnervating the rat iris. Z Zellforsch Mikrosk Anat 1972; 135:175-194.
34. Stenevi U, Bjorklund A, Svendgaard NA. Transplantation of central and peripheral monoamine neurons to the adult rat brain: Techniques and conditions for survival. Brain Res 1976; 114:1-20.
35. Bjorklund A, Stenevi U, Svendgaard N. Growth of transplanted monoaminergic neurones into the adult hippocampus along the perforant path. Nature 1976; 262:787-790.
36. Perlow MJ, Freed WJ, Hoffer BJ et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204:643-647.
37. Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res 1979; 177:555-560.
38. Dunnett SB, Bjorklund A, Schmidt RH et al. Intracerebral grafting of neuronal cell suspensions. V. Behavioural recovery in rats with bilateral 6-OHDA lesions following implantation of nigral cell suspensions. Acta Physiol Scand Suppl 1983a; 522:39-47.
39. Dunnett SB, Bjorklund A, Schmidt RH et al. Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites. Acta Physiol Scand Suppl 1983b; 522:29-37.
40. Schmidt RH, Bjorklund A, Stenevi U et al. Intracerebral grafting of neuronal cell suspensions. III. Activity of intrastriatal nigral suspension implants as assessed by measurements of dopamine synthesis and metabolism. Acta Physiol Scand Suppl 1983; 522:19-28.
41. Dunnett SB, Bjorklund A, Stenevi U et al. Grafts of embryonic substantia nigra reinnervating the ventrolateral striatum ameliorate sensorimotor impairments and akinesia in rats with 6-OHDA lesions of the nigrostriatal pathway. Brain Res 1981; 229:209-217.
42. Dunnett SB. Anatomical and behavioral consequences of cholinergic-rich grafts to the neocortex of rats with lesions of the nucleus basalis magnocellularis. Ann NY Acad Sci 1987; 495:415-430.
43. Mandel RJ, Brundin P, Bjorklund A. The importance of graft placement and task complexity for transplant- induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats. Eur J Neurosci 1990; 2:888-894.
44. Mahalik TJ, Finger TE, Stromberg I et al. Substantia nigra transplants into denervated striatum of the rat: Ultrastructure of graft and host interconnections. J Comp Neurol 1985; 240:60-70.
45. Freund TF, Bolam JP, Bjorklund A et al. Efferent synaptic connections of grafted dopaminergic neurons reinnervating the host neostriatum: A tyrosine hydroxylase immunocytochemical study. J Neurosci 1985; 5:603-616.
46. Zetterstrom T, Brundin P, Gage FH et al. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 1986; 362:344-349.
47. Strecker RE, Sharp T, Brundin P et al. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987; 22:169-178.
48. Arbuthnott G, Dunnett S, MacLeod N. Electrophysiological properties of single units in dopamine-rich mesencephalic transplants in rat brain. Neurosci Lett 1985; 57:205-210.
49. Doucet G, Murata Y, Brundin P et al. Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol 1989; 106:1-19.
50. Brundin P, Duan W, Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett SaBA, ed. Functional neural transplantation. New York: Raven Press, 1994:9-46.
51. Lindvall O. Clinical application of neuronal grafts in Parkinson's disease. J Neurol 1994; 242:554-56.
52. Bjorklund A, Kirik D, Rosenblad C et al. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 886:82-98.
53. Lindvall O, Rehncrona S, Gustavii B et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 1988; 2:1483-1484.
54. Lindvall O, Rehncrona S, Brundin P et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989; 46:615-631.
55. Madrazo I, Leon V, Torres C et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson's disease. N Engl J Med 1988; 318:51.
56. Madrazo I, FrancoBourland R, Ostrosky-Solis F et al. Fetal homotransplants (ventral mesencephalon and adrenal tissue) to the striatum of parkinsonian subjects. Arch Neurol 1990b; 47:1281-1285.
57. Madrazo I, FrancoBourland R, Ostrosky-Solis F et al. Neural transplantation (auto-adrenal, fetal nigral and fetal adrenal) in Parkinson's disease: The Mexican experience. Prog Brain Res 1990a; 82:593-602.
58. Backlund EO, Granberg PO, Hamberger B et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 1985; 62:169-173-
59. Lindvall O, Backlund EO, Farde L et al. Transplantation in Parkinson's disease: Two cases of adrenal medullary grafts to the putamen. Ann Neurol 1987; 22:457-468.
60. Madrazo I, Drucker-Colin R, Diaz V et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 1987; 316:831-834.
61. Goetz CG, Stebbins IIIrd GT, Klawans HL et al. United parkinson foundation neurotransplantation registry on adrenal medullary transplants: Presurgical, and 1- and 2-year follow-up. Neurology 1991; 41:1719-1722.
62. Quinn N. The modern management of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990; 53:93-95.
63. Espejo EF, Montoro RJ, Armengol JA et al. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 1998; 20:197-206.
64. Luquin MR, Montoro RJ, Guillen J et al. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999; 22:743-750.
65. Itakura T, Komai N, Ryujin Y et al. Autologous transplantation of the cervical sympathetic ganglion into the parkinsonian brain: Case report. Neurosurgery 1994; 35:155-157, (discussion 157-158).
66. Itakura T, Uematsu Y, Nakao N et al. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases. Stereotact Funct Neurosurg 1997; 69:112-115.
67. Subramanian T. Cell transplantation for the treatment of Parkinson's disease. Semin Neurol 2001; 21:103-115.
68. Lindvall O, Rehncrona S, Brundin P et al. Neural transplantation in Parkinson's disease: The Swedish experience. Prog Brain Res 1990b; 82:729-734.
69. Brundin P, Hagell, Peter. The neurobiology of cell transplantation in Parkinsons's disease. Clinical Neuroscience Research 2001; 1:507-520.
70. Defer GL, Geny C, Ricolfi F et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996; 119:41-50.
71. Hauser RA, Freeman TB, Snow BJ et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56:179-187.
72. Mendez I, Dagher A, Hong M et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J Neurosurg 2000; 92:863-869.
73. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996; 19:102-109.
74. Brundin P, Pogarell O, Hagell P et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000b; 123:1380-1390.
75. Hagell P, Schrag A, Piccini P et al. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 1999; 122:1121-1132.
76. Freed CR, Greene PE, Breeze RE et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344:710-719.
77. Piccini P, Brooks DJ, Bjorklund A et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999; 2:1137-1140.
78. Piccini P, Lindvall O, Bjorklund A et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000; 48:689-695.
79. Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 2001; 60:741-752.
80. Brundin P. Dissection, preparation and implantation of human embryonic brain tissue. In: SB, Dunnett AB, eds. Neural Transplantation, A Practical approach. Oxford: University Press, 1992:139-160.
81. Freeman TB, Spence MS, Boss BD et al. Development of dopaminergic neurons in the human substantia nigra. Exp Neurol 1991; 113:344-353.
82. Boer GJ. Ethical guidelines for the use of human embryonic or fetal tissue for experimental and clinical neurotransplantation and research. Network of European CNS Transplantation and Restoration (NECTAR). J Neurol 1994; 242:1-13.
83. Freed CR, Breeze RE, Rosenberg NL et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol 1990a; 47:505-512.
84. Petersen A, Hansson O, Emgard M et al. Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor. Cell Transplant 2000; 9:577-584.
85. Freeman TB, Sanberg PR, Nauert GM et al. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts. Cell Transplant 1995a; 4:141-154.
86. Folkerth RD, Durso R. Survival and proliferation of nonneural tissues, with obstruction of cerebral ventricles, in a parkinsonian patient treated with fetal allografts. Neurology 1996; 46:1219-1225.
87. Mamelak AN, Eggerding FA, Oh DS et al. Fatal cyst formation after fetal mesencephalic allograft transplant for Parkinson's disease. J Neurosurg 1998; 89:592-598.
88. Pakkenberg B, Moller A, Gundersen HJ et al. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased ste-reological method. J Neurol Neurosurg Psychiatry 1991; 54:30-33.
89. Frodl EM, Duan WM, Sauer H et al. Human embryonic dopamine neurons xenografted to the rat: Effects of cryopreservation and varying regional source of donor cells on transplant survival, morphology and function. Brain Res 1994; 647:286-298.
90. Kordower J, Habury H, Bankiewicz KS. Neuropathology of dopaminergic transplants in patient's with Parkinson's disease. In: FTaW H, ed. Cell transplantation for neurological disorders: Towards reconstruction of the human central nervous system. Totowa, NJ: Humana Press, 1998:51-75.
91. Nakao N, Frodl EM, Duan WM et al. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc Natl Acad Sci USA 1994; 91:12408-12412.
92. Clarkson ED, Freed CR. Development of fetal neural transplantation as a treatment for Parkinson's disease. Life Sci 1999; 65:2427-2437.
93. Freeman TB, Olanow CW, Hauser RA et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995b; 38:379-388.
94. Freed CR, Breeze RE, Rosenberg NL et al. Therapeutic effects of human fetal dopamine cells transplanted in a patient with Parkinson's disease. Prog Brain Res 1990b; 82:715-721.
95. Sauer H, Frodl EM, Kupsch A et al. Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease. Exp Brain Res 1992; 90:54-62.
96. Zawada WM, Zastrow DJ, Clarkson ED et al. Growth factors improve immediate survival of embryonic dopamine neurons after transplantation into rats. Brain Res 1998; 786:96-103.
97. Hagell P, Piccini P, Bjorklund A et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002b; 5:627-628.
98. Brundin P, Strecker RE, Widner H et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: Immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988; 70:192-208.
99. Forni C, Brundin P, Strecker RE et al. Time-course of recovery of dopamine neuron activity during reinnervation of the denervated striatum by fetal mesencephalic grafts as assessed by in vivo voltammetry. Exp Brain Res 1989; 76:75-87.
100. Brundin P, Strecker RE, Lindvall O et al. Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease. Ann NY Acad Sci 1987; 495:473-496.
101. Lindvall O, Brundin P, Widner H et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990a; 247:574-577.
102. Peschanski M, Defer G, N'Guyen JP et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994; 117:487-499.
103. Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994; 117:859-876.
104. Holthoff-Detto VA, Kessler J, Herholz K et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol 1997; 54:145-150.
105. Annett LE, Torres EM, Ridley RM et al. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6- OHDA lesions. Exp Brain Res 1995; 103:355-371.
106. Widner H, Brundin P. Immunological aspects of grafting in the mammalian central nervous system. A review and speculative synthesis. Brain Res 1988; 472:287-324.
107. Brundin P, Widner H, Nilsson OG et al. Intracerebral xenografts of dopamine neurons: The rôle of immunosuppression and the blood-brain barrier. Exp Brain Res 1989; 75:195-207.
108. Brevig T, Holgersson J, Widner H. Xenotransplantation for CNS repair: Immunological barriers and strategies to overcome them. Trends Neurosci 2000; 23:337-344.
109. Widner H. Transplantation of neuronal and nonneuronal cells into the brain. Immune Response in the Nervous System. 2 Edition. In: Rothwell N, ed. Bios Scientific Publishers, 2002:189-217.
110. Duan WM, Cameron RM, Brundin P et al. Rat intrastriatal neural allografts challenged with skin allografts at different time points. Exp Neurol 1997b; 148:334-347.
111. Duan WM, Brundin P, Widner H. Addition of allogeneic spleen cells causes rejection of intrastriatal embryonic mesencephalic allografts in the rat. Neuroscience 1997a; 77:599-609.
112. Kordower JH, Goetz CG, Freeman TB et al. Dopaminergic transplants in patients with Parkinson's disease: Neuroanatomical correlates of clinical recovery. Exp Neurol 1997a; 144:41-46.
113. Widner H. The lund transplant program for parkinson's disease and patients with MPTP-Induced parkinsonism. In: FTaW H, ed. Cell transplantation for Neurological Disorders: Toward Reconstruction of the Human Central Nervous System. Totowa, NJ: Humana Press Inc.,1998:1-17.
114. Widner H. Immunological issues in rodent and primate transplants (Allografts). In: FTaW H, ed. Cell transplantation for Neurological Disorders: Toward Reconstruction of the Human Central Nervous System. Totowa, NJ: Humana Press Inc.,1998a:171-187.
115. Kordower JH, Freeman TB, Snow BJ et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995; 332:1118-1124.
116. Wenning GK, Odin P, Morrish P et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997; 42:95-107.
117. Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog Brain Res 2000; 127:299-320.
118. Freed C, Breeze RE, Fahn S et al. Preoperative response to Levadopa is the best predictor of transplant outcome. Ann Neurology 2004; 6:846.
119. Kordower JH, Rosenstein JM, Collier TJ et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996; 370:203-230.
120. Kordower JH, Freeman TB, Chen EY et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998b; 13:383-393.
121. Kordower JH, Styren S, Clarke M et al. Fetal grafting for Parkinson's disease: Expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997b; 6:213-219.
122. Defer GL, Widner H, Marie RM et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999; 14:572-584.
123. Langston JW, Widner H, Goetz CG et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992; 7:2-13.
124. van Hilten JJ, van der Zwan AD, Zwinderman AH et al. Rating impairment and disability in Parkinson's disease: Evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord 1994; 9:84-88.
125. Hagell P, Crabb L, Pogarell O et al. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Mov Disord 2000; 15:224-229.
126. Lindvall O, Sawle G, Widner H et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994; 35:172-180.
127. Widner H, Tetrud J, Rehncrona S et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). N Engl J Med 1992; 327:1556-1563.
128. Baker KK, Ramig LO, Johnson AB et al. Preliminary voice and speech analysis following fetal dopamine transplants in 5 individuals with Parkinson disease. J Speech Lang Hear Res 1997; 40:615-626.
129. Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl 2000; 60:125-137.
130. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996; 119:585-591.
131. Remy P, Samson Y, Hantraye P et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Ann Neurol 1995; 38:580-588.
132. Snow BJ, Tooyama I, McGeer EG et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34:324-330.
133. Rinne UK, Laihinen A, Rinne JO et al. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 1990; 5:55-59.
134. Brooks DJ, Ibanez V, Sawle GV et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
135. Redmond Jr DE, Leranth C, Spencer DD et al. Fetal neural graft survival. Lancet 1990; 336:820-822.
136. Henderson BT, Clough CG, Hughes RC et al. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 1991; 48:822-827.
137. Hitchcock E. Stereotactic neural transplantation. Stereotact Funct Neurosurg 1994; 62:120-133.
138. Freed CR, Breeze RE, Fahn S. Placebo surgery in trials of therapy for Parkinson's disease. N Engl J Med 2000; 342:353-354, (discussion 354-355).
139. Kordower JH, Freeman TB, Olanow CW. Neuropathology of fetal nigral grafts in patients with Parkinson's disease. Mov Disord 1998a; 13:88-95.
140. Brundin P, Dunnett S, Bjorklund A et al. Transplanted dopaminergic neurons: More or less? Nat Med 2001; 7:512-513.
141. Olanow CW, Freeman T, Kordower J. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 345:146, (discussion 147).
142. Redmond Jr DE, Sladek JR, Spencer DD. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 345:146-147.
143. Hagell P, Piccini P, Bjorklund A et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002a; 3:3.
144. 143a. Olanow CW, Goetz CG, Kordower JH et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54:403-414.
145. Lee CS, Cenci MA, Schulzer M et al. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000a; 123:1365-1379.
146. Castilho RF, Hansson O, Brundin P. Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Prog Brain Res 2000b; 127:203-231.
147. Brundin P, Karlsson J, Emgard M et al. Improving the survival of grafted dopaminergic neurons: A review over current approaches. Cell Transplant 2000a; 9:179-195.
148. Glozman S, Yavin E. Lipid peroxides are generated by the fetal rat brain after episodes of global ischemia in utero. Neurochem Res 1997; 22:201-208.
149. Emgard M, Blomgren K, Brundin P. Characterisation of cell damage and death in embryonic mesencephalic tissue: a study on ultrastructure, vital stains and protease activity. Neuroscience 2002; 115(4):1177-1187.
150. Fawcett JW, Barker RA, Dunnett SB. Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional and monolayer cultures of embryonic rat ventral mesencephalon. Exp Brain Res 1995; 106:275-282.
151. Schierle GS, Brundin P. Excitotoxicity plays a role in the death of tyrosine hydroxylase-immunopositive nigral neurons cultured in serum-free medium. Exp Neurol 1999; 157:338-348.
152. Emgard M, Karlsson J, Hansson O et al. Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts. Exp Neurol 1999; 160:279-288.
153. Takei M, Hiramatsu M, Mori A. Inhibitory effects of calcium antagonists on mitochondrial swelling induced by lipid peroxidation or arachidonic acid in the rat brain in vitro. Neurochem Res 1994; 19:1199-1206.
154. Kaminski Schierle GS, Hansson O, Brundin P. Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience 1999; 94:17-20.
155. Braughler JM, Pregenzer JF. The 21-aminosteroid inhibitors of lipid peroxidation: Reactions with lipid peroxyl and phenoxy radicals. Free Radice Biol Med 1989; 7:125-130.
156. Karlsson J, Love RM, Clarke DJ et al. Effects of anaesthetics and lazaroid U-83836E on survival of transplanted rat dopaminergic neurones. Brain Res 1999; 821:546-550.
157. Schierle GS, Hansson O, Leist M et al. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 1999; 5:97-100.
158. Pettmann B, Henderson CE. Neuronal cell death. Neuron 1998; 20:633-647.
159. Hansson O, Castilho RF, Kaminski Schierle GS et al. Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. Exp Neurol 2000; 164:102-111.
160. Gray J, Haran MM, Schneider K et al. Evidence that inhibition of cathepsin-B contributes to the neuroprotective properties of caspase inhibitor Tyr-Val-Ala-Asp- chloromethyl ketone. J Biol Chem 2001; 276:32750-32755.
161. Castilho RF, Hansson O, Brundin P. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. Exp Neurol 2000a; 164:94-101.
162. Mayer E, Dunnett SB, Pellitteri R et al. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons-I. Effects in vitro. Neuroscience 1993; 56:379-388.
163. Takayama H, Ray J, Raymon HK et al. Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1995; 1:53-58.
164. Zeng BY, Jenner P, Marsden CD. Altered motor function and graft survival produced by basic fibroblast growth factor in rats with 6-OHDA lesions and fetal ventral mesencephalic grafts are associated with glial proliferation. Exp Neurol 1996; 139:214-226.
165. Rosenblad C, Martinez-Serrano A, Bjorklund A. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996; 75:979-985.
166. Sinclair SR, Svendsen CN, Torres EM et al. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 1996; 7:2547-2552.
167. Ahn Y-H, Bensadoun J-C, Aebischer P. Increased fiber outgrowth from xeno-transplanted human embryonic dopaminergic neurons with coimplants of polymer-encapsulated genetically modified cells releasing glial-cell line derived neurotrophic factor. Brain Res Bull; 66(2):135-42.
168. Karlsson J, Emgard M, Brundin P. Comparison between survival of lazaroid-treated embryonic nigral neurons in cell suspension, cultures and transplants. Brain Res 2002; 955(1-2):268-280.
169. Duan WM, Zhao LR, Westerman M et al. Enhancement of nigral graft survival in rat brain with the systemic administration of synthetic fibronectin peptide V. Neuroscience 2000; 100:521-530.
170. Karlsson J, Emgard M, Gido G et al. Increased survival of embryonic nigral neurons when grafted to hypothermic rats. Neuroreport 2000; 11:1665-1668.
171. Karlsson J, Petersen A, Gido G et al. Combined caspase inhibitor and lazaroid pretreatment of embryonic donor tissue with mild hypothermia of the graft recipient-effects on the survival of the transplanted dopaminergic neurons and nondopaminergic cells. Submitted 2002b.
172. Freeman TB, Wojak JC, Brandeis L et al. Cross-species intracerebral grafting of embryonic swine dopaminergic neurons. Prog Brain Res 1988; 78:473-477.
173. Edge AS, Gosse ME, Dinsmore J. Xenogeneic cell therapy: Current progress and future developments in porcine cell transplantation. Cell Transplant 1998; 7:525-539.
174. Barker RA, Kendall AL, Widner H. Neural tissue xenotransplantation: What is needed prior to clinical trials in Parkinson's disease? Neural Tissue Xenografting Project. Cell Transplant 2000; 9:235-246.
175. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1:964-966.
176. Isacson O, Deacon TW, Pakzaban P et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995; 1:1189-1194.
177. Galpern WR, Burns LH, Deacon TW et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: Functional recovery and graft morphology. Exp Neurol 1996; 140:1-13.
178. Larsson LC, Czech KA, Brundin P et al. Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats: Immune responses and functional effects. Cell Transplant 2000; 9:261-272.
179. Michaels MG, McMichael JP, Brasky K et al. Screening donors for xenotransplantation. The potential for xenozoonoses. Transplantation 1994; 57:1462-1465.
180. Heneine W, Tibell A, Switzer WM et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998; 352:695-699.
181. Paradis K, Langford G, Long Z et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. The XEN 111 Study Group. Science 1999; 285:1236-1241.
182. Dobson R. Cloning of pigs bring xenotransplants closer. Bmj 2000; 320:826.
183. Pakzaban P, Deacon TW, Burns LH et al. A novel mode of immunoprotection of neural xenotransplants: Masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 1995; 65:983-996.
184. Schumacher JM, Ellias SA, Palmer EP et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000; 54:1042-1050.
185. Deacon T, Schumacher J, Dinsmore J et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3:350-353.
186. Freeman TBW, Hauser RL, Bakay RA et al. A Prospective, randomized, double-blind, surgical placebo-controlled trial of intrastriatal transplantation of fetal porcine ventral mesencephalic tissue (Neurocell-PD) in subjects with
187. Lee SH, Lumelsky N, Studer L et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000b; 18:675-679.
188. Kawasaki H, Mizuseki K, Nishikawa S et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000; 28:31-40.
189. Kawasaki H, Suemori H, Mizuseki K et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci USA 2002; 99:1580-1585.
190. Kim JH, Auerbach JM, Rodriguez-Gomez JA et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 20:20.
191. Bjorklund LM, Sanchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99:2344-2349.
192. Perrier AL, Tabar V, Barberi T et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101:12543-12548.
193. Zeng X, Cai J, Chen J et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 2004; 22:925-940.
194. Park S, Lee KS, Lee YJ et al. Generation of dopaminergic neurons in vitro from human embryonic stem cells treated with neurotrophic factors. Neurosci Lett 2004; 359:99-103.
195. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145-1147.
196. Paul G, Li JY, Brundin P. Stem cells: Hype or hope? Drug Discov Today 2002; 7:295-302.
197. Daadi MM, Weiss S. Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. J Neurosci 1999; 19:4484-4497.
198. Daadi M, Arcellana-Panlilio MY, Weiss S. Activin cooperates with fibroblast growth factor 2 to regulate tyrosine hydroxylase expression in the basal forebrain ventricular zone progenitors. Neuroscience 1998; 86:867-880.
199. Stull ND, Iacovitti L. Sonic hedgehog and fgf8: Inadequate signals for the differentiation of a dopamine phenotype in mouse and human neurons in culture. Exp Neurol 2001; 169:36-43.
200. Theofilopoulos S, Goggi J, Riaz SS et al. Parallel induction of the formation of dopamine and its metabolites with induction of tyrosine hydroxylase expression in foetal rat and human cerebral cortical cells by brain-derived neurotrophic factor and glial-cell derived neurotrophic factor. Brain Res Dev Brain Res 2001; 127:111-122.
201. Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998; 1:290-295.
202. Ling ZD, Potter ED, Lipton JW et al. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol 1998; 149:411-423.
203. Potter ED, Ling ZD, Carvey PM. Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res 1999; 296:235-246.
204. Studer L, Csete M, Lee SH et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci 2000; 20:7377-7383.
205. Carvey PM, Ling ZD, Sortwell CE et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: A source of cells for transplantation in Parkinson's disease. Exp Neurol 2001; 171:98-108.
206. Brundin P, Bjorklund A. Survival of expanded dopaminergic precursors is critical for clinical trials. Nat Neurosci 1998; 1:537.
207. Storch A, Paul G, Csete M et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 2001; 170:317-325.
208. Svendsen CN, Caldwell MA, Shen J et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol 1997; 148:135-146.
209. Gage FH. Mammalian neural stem cells. Science 2000; 287:1433-1438.
210. 208a. Zhao M, Momma S, Delfani K et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 2003; 100:7925-7930.
211. Frielingsdorf H, Schwarz K, Brundin P et al. No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. Proc Natl Acad Sci USA 2004; 101:10177-10182.
212. 209a. Cooper O, Isacson O. Intrastriatal transforming growth factor alpha delivery to a model of Parkinson's disease induces proliferation and migration of endogenous adult neural progenitor cells without differentiation into dopaminergic neurons. J Neurosci 2004; 24:8924-8931
213. Lie DC, Dziewczapolski G, Willhoite AR et al. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002; 22:6639-6649.
214. 210a. Bjornson CR, Rietze RL, Reynolds BA et al. Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999; 283:534-537.
215. Morshead CM, Benveniste P, Iscove NN et al. Hematopoietic competence is a rare property of neural stem cells that may depend on genetic and epigenetic alterations. Nat Med 2002; 8:268-273.
216. Galli R, Borello U, Gritti A et al. Skeletal myogenic potential of human and mouse neural stem cells [In Process Citation]. Nat Neurosci 2000; 3:986-991.
217. Rietze RL, Valcanis H, Brooker GF et al. Purification of a pluripotent neural stem cell from the adult mouse brain. Nature 2001; 412:736-739.
218. Clarke DL, Johansson CB, Wilbertz J et al. Generalized potential of adult neural stem cells. Science 2000; 288:1660-1663.
219. Palmer TD, Schwartz PH, Taupin P et al. Cell culture. Progenitor cells from human brain after death. Nature 2001; 411:42-43.
220. Song H, Stevens CF, Gage FH. Astroglia induce neurogenesis from adult neural stem cells. Nature 2002; 417:39-44.
221. Rossi F, Cattaneo E. Opinion: Neural stem cell therapy for neurological diseases: Dreams and reality. Nat Rev Neurosci 2002; 3:401-409.
222. Brazelton TR, Rossi FM, Keshet GI et al. From marrow to brain: Expression of neuronal pheno-types in adult mice. Science 2000; 290:1775-1779.
223. Mezey E, Chandross KJ, Harta G et al. Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000; 290:1779-1782.
224. Priller J, Persons DA, Klett FF et al. Neogenesis of cerebellar Purkinje neurons from gene-marked bone marrow cells in vivo. J Cell Biol 2001; 155:733-738.
225. Sasaki M, Honmou O, Akiyama Y et al. Transplantation of an acutely isolated bone marrow fraction repairs demyelinated adult rat spinal cord axons. Glia 2001; 35:26-34.
226. Zhao LR, Duan WM, Reyes M et al. Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002; 174:11-20.
227. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 20:20.
228. 223a. Hermann A, Gastl R, Liebau S et al. Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci 2004; 117:4411-4422.
229. Toma JG, Akhavan M, Fernandes KJ et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001; 3:778-784.
230. 224a. Joannides A, Gaughwin P, Schwiening C et al. Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-derived stem cells. Lancet 2004; 364:172-178
231. Zuk PA, Zhu M, Mizuno H et al. Multilineage cells from human adipose tissue: Implications for cell- based therapies. Tissue Eng 2001; 7:211-228.